Corbus Pharmaceuticals Holdings Future Growth
Future criteria checks 2/6
Corbus Pharmaceuticals Holdings's earnings are forecast to decline at 32.4% per annum while its annual revenue is expected to grow at 79% per year. EPS is expected to decline by 14.2% per annum.
Key information
-32.4%
Earnings growth rate
-14.2%
EPS growth rate
Biotechs earnings growth | 28.4% |
Revenue growth rate | 79.0% |
Future return on equity | n/a |
Analyst coverage | Good |
Last updated | 14 Nov 2024 |
Recent future growth updates
Recent updates
Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies
Nov 11Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug
Jan 30Corbus Pharmaceuticals GAAP EPS of -$0.11
Aug 09Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Using Too Much Debt?
Nov 19Here's Why Shareholders Should Examine Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Compensation Package More Closely
Jun 12Should Shareholders Reconsider Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Compensation Package?
May 14What Kind Of Shareholders Hold The Majority In Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) Shares?
Mar 11Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Weighed On By Its Debt Load?
Feb 04Corbus Pharmaceuticals: Down But Not Out
Jan 29Have Insiders Been Buying Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares This Year?
Jan 09Corbus's lenabasum shows benefit in autoimmune disorder
Nov 09Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 5 | -88 | -65 | N/A | 7 |
12/31/2025 | 1 | -66 | -50 | N/A | 7 |
12/31/2024 | N/A | -46 | -50 | -32 | 7 |
9/30/2024 | N/A | -39 | -37 | -37 | N/A |
6/30/2024 | N/A | -35 | -30 | -30 | N/A |
3/31/2024 | N/A | -34 | -29 | -29 | N/A |
12/31/2023 | N/A | -45 | -36 | -36 | N/A |
9/30/2023 | N/A | -47 | -38 | -38 | N/A |
6/30/2023 | N/A | -46 | -38 | -38 | N/A |
3/31/2023 | N/A | -51 | -42 | -42 | N/A |
12/31/2022 | N/A | -42 | -38 | -38 | N/A |
9/30/2022 | N/A | -42 | -40 | -40 | N/A |
6/30/2022 | 0 | -35 | -32 | -32 | N/A |
3/31/2022 | 0 | -39 | -37 | -37 | N/A |
12/31/2021 | 1 | -46 | -48 | -48 | N/A |
9/30/2021 | 2 | -44 | -57 | -57 | N/A |
6/30/2021 | 3 | -77 | -85 | -85 | N/A |
3/31/2021 | 3 | -98 | -94 | -94 | N/A |
12/31/2020 | 4 | -111 | -100 | -100 | N/A |
9/30/2020 | 6 | -129 | -106 | -104 | N/A |
6/30/2020 | 7 | -115 | -97 | -94 | N/A |
3/31/2020 | 36 | -75 | -87 | -84 | N/A |
12/31/2019 | 36 | -71 | -48 | -46 | N/A |
9/30/2019 | 35 | -62 | -39 | -37 | N/A |
6/30/2019 | 34 | -56 | -30 | -29 | N/A |
3/31/2019 | 6 | -70 | -19 | -18 | N/A |
12/31/2018 | 5 | -56 | -32 | -30 | N/A |
9/30/2018 | 3 | -49 | -28 | -25 | N/A |
6/30/2018 | 3 | -41 | N/A | -23 | N/A |
3/31/2018 | 2 | -37 | N/A | -23 | N/A |
12/31/2017 | 2 | -32 | N/A | -28 | N/A |
9/30/2017 | 3 | -29 | N/A | -24 | N/A |
6/30/2017 | 3 | -28 | N/A | -21 | N/A |
3/31/2017 | 3 | -25 | N/A | -18 | N/A |
12/31/2016 | 2 | -20 | N/A | -14 | N/A |
9/30/2016 | 2 | -15 | N/A | -9 | N/A |
6/30/2016 | 1 | -12 | N/A | -8 | N/A |
3/31/2016 | 1 | -10 | N/A | -6 | N/A |
12/31/2015 | 1 | -9 | N/A | -5 | N/A |
9/30/2015 | 0 | -8 | N/A | -5 | N/A |
6/30/2015 | 0 | -6 | N/A | -3 | N/A |
3/31/2015 | N/A | -4 | N/A | -4 | N/A |
12/31/2014 | N/A | -3 | N/A | -2 | N/A |
9/30/2014 | N/A | -2 | N/A | -1 | N/A |
6/30/2014 | N/A | -1 | N/A | -1 | N/A |
3/31/2014 | N/A | -1 | N/A | 0 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CRBP is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CRBP is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CRBP is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CRBP's revenue (79% per year) is forecast to grow faster than the US market (9% per year).
High Growth Revenue: CRBP's revenue (79% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if CRBP's Return on Equity is forecast to be high in 3 years time